| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/28/2005 | WO2005023291A3 Use of glp1-agonists in the treatment of patients with type i diabetes |
| 04/28/2005 | WO2005021495A3 Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones |
| 04/28/2005 | WO2005018622A8 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| 04/28/2005 | WO2005011581A3 Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 04/28/2005 | WO2004098634A3 Protein arginine n-methyltransferase 2 (prmt-2) |
| 04/28/2005 | WO2004014842A8 Acylated arylcycloalkylamines and their use as pharmaceuticals |
| 04/28/2005 | WO2004005262A8 New neuropeptide y y5 receptor antagonists |
| 04/28/2005 | WO2003099201A3 Compositions and methods of use for a fibroblast growth factor |
| 04/28/2005 | WO2003044170A3 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 04/28/2005 | US20050090669 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists |
| 04/28/2005 | US20050090555 Compound for the treatment of metabolic disorders |
| 04/28/2005 | US20050090543 Method for the preparation of tetrahydrobenzothiepines |
| 04/28/2005 | US20050090542 crystalline polymorphic dosage forms of anticholesterol agents; statins |
| 04/28/2005 | US20050090536 Substituted pyrrol-3-ylisoxazoles, e.g., N-benzyl-4-[4-(o-chlorophenyl)-5-isoxazolyl)pyrrole-2-carboxamide; treating diseases that are alleviated by a protein kinase inhibitor, particularly cancer, inflammatory disorders, restenosis, and cardiovascular disease. |
| 04/28/2005 | US20050090534 5-carbonyl or carbamido-4-(4-chlorophenyl)-2-heteroaryl oxazoles; analgesic for diabetic neuropathy |
| 04/28/2005 | US20050090530 5-(4-(2-(n-methyl-n-(2-pyridyl)amido)ethoxy)benzyl)thiazolidine-2, 4-dione and pharmaceutical compositions comprising the same |
| 04/28/2005 | US20050090524 Novel adamantane derivatives |
| 04/28/2005 | US20050090519 1-Alkyl-4-(3-substitutedphenyl)piperidines |
| 04/28/2005 | US20050090503 5-HT receptor ligands and uses thereof |
| 04/28/2005 | US20050090502 Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents |
| 04/28/2005 | US20050090501 Heteroaryl-cyclic acetals |
| 04/28/2005 | US20050090496 Sulphonyl compounds with 5-ht6 receptor affinity |
| 04/28/2005 | US20050090491 2'-Methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/28/2005 | US20050090490 3-Substituted-4-pyrimidone derivatives |
| 04/28/2005 | US20050090485 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders |
| 04/28/2005 | US20050090483 Purine derivatives as kinase inhibitors |
| 04/28/2005 | US20050090472 Xanthine oxidase inhibitors |
| 04/28/2005 | US20050090457 Method of treating mammals with genistein and/or genistein analogues |
| 04/28/2005 | US20050090424 Administering concurrent with cell grafting surgery using insulin producing stem cells |
| 04/28/2005 | US20050089938 For treatment of epilepsy, hypertension, angina pectoris, cerebral ischaemia, Parkinson's disease, insulin-dependent diabetes, and/or Lambert-Eaton myasthenic syndrome |
| 04/28/2005 | US20050089933 Compositions and methods for surrogate antibody modulation of an immune response and transport |
| 04/28/2005 | US20050089911 87 human secreted proteins |
| 04/28/2005 | US20050089866 Identifying modulators for the treatment and prevention of diabetes, pain, obesity, nervous system, inflammatory, cell proliferative and liver disorders |
| 04/28/2005 | US20050089573 Oral pharmaceutical formulation containing ibandronate |
| 04/28/2005 | US20050089530 Selenium yeast product, a method of preparing a selenium yeast product and the use of the product for preparing food, a dietary supplement or a drug |
| 04/28/2005 | US20050087198 Method for systemic drug delivery through the nail |
| 04/28/2005 | CA2543447A1 Antibody and use of the same |
| 04/28/2005 | CA2542755A1 Biguanide drug-containing jelly preparation |
| 04/28/2005 | CA2542504A1 Lipids containing omega-3 and omega-6 fatty acids |
| 04/28/2005 | CA2542290A1 Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof |
| 04/28/2005 | CA2541751A1 Phenoxyether derivatives as ppar modulators |
| 04/27/2005 | EP1526141A2 MHC complexes and uses thereof |
| 04/27/2005 | EP1526134A2 Triazolyl tropane derivatives as ccr5 modulators |
| 04/27/2005 | EP1525883A1 Ciclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 04/27/2005 | EP1525323A2 Pgc-beta, a novel pgc-1 homologue and uses therefor |
| 04/27/2005 | EP1525306A1 Three-dimensional structure of dipeptidyl peptidase iv |
| 04/27/2005 | EP1525219A1 Glp-1 and methods for treating diabetes |
| 04/27/2005 | EP1525208A2 Novel difluorinated gem compounds, preparation methods thereof and applications of same |
| 04/27/2005 | EP1525204A1 Phenylalanine enamide derivatives |
| 04/27/2005 | EP1525201A1 Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor |
| 04/27/2005 | EP1525200A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 04/27/2005 | EP1525199A1 Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| 04/27/2005 | EP1525198A2 Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof |
| 04/27/2005 | EP1525194A1 Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
| 04/27/2005 | EP1525185A1 Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| 04/27/2005 | EP1525000A2 Gastrointestinal delivery of genetic material coupled to a transporting agent |
| 04/27/2005 | EP1524997A1 Stable liquid parenteral parecoxib formulation |
| 04/27/2005 | EP1524996A2 Combination of pde5 inhibitors with angiotensin ii receptor antagonists |
| 04/27/2005 | EP1524980A1 Phenylalanine enamide derivatives containing a spiro[3.5]non-1-ene ring for use as integrin inhibitors |
| 04/27/2005 | EP1463723A4 Process for the preparation of simvastatin |
| 04/27/2005 | EP1429628B1 Mixture of base-containing micronutrient substances |
| 04/27/2005 | EP1423367B1 Solvates of lercanidipine hydrochloride and crystalline forms of lercanidipine hydrochloride |
| 04/27/2005 | EP1419150B1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 04/27/2005 | EP1373202B1 Preparation of non-crystalline atorvastatin calcium |
| 04/27/2005 | EP1366033B1 Chemical compounds |
| 04/27/2005 | EP1311257B1 Compositions containing hypoglycemically active stilbenoids |
| 04/27/2005 | EP1289519A4 Methods of treating androgen deficiency in men using selective antiestrogens |
| 04/27/2005 | EP1225814B1 Fibrous-liponutritional complexes and compositions containing them |
| 04/27/2005 | EP1220620B1 Composition comprising casein protein and whey protein |
| 04/27/2005 | EP1143974B1 Pharmaceutical compositions for alleviating discomfort |
| 04/27/2005 | EP1128834B1 Combinations for diabetes which contain glyburide,troglitazone (and a biguanide) |
| 04/27/2005 | EP1105122B1 Pharmaceutical compositions containing lipase inhibitors |
| 04/27/2005 | EP1040098B1 Integrin receptor antagonists |
| 04/27/2005 | EP1011651B1 Method of treating diabetes and related disease states |
| 04/27/2005 | EP0918515B1 USE OF INHIBITORS OF THE CELLULAR Na+ /H+ EXCHANGER (NHE) FOR PREPARING A MEDICAMENT FOR NORMALIZING SERUM LIPIDS |
| 04/27/2005 | CN1610693A Transdifferentiation of pancreatic acinar cells |
| 04/27/2005 | CN1610691A 2-O-(beta-D-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it |
| 04/27/2005 | CN1610684A Novel multi-ring organic compounds for regulating gut motility and food intake |
| 04/27/2005 | CN1610683A Pyrimidotriazines as phosphatase inhibitors |
| 04/27/2005 | CN1610674A Use of 2-amino-thiazoline derivatives as inhibitors of inducible NO-synthase |
| 04/27/2005 | CN1610671A Quinoline compounds with 5-HT-antagonistic properties for therapy |
| 04/27/2005 | CN1610669A Heteroaryl-substituted aminocyclohexane derivatives |
| 04/27/2005 | CN1610664A 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists |
| 04/27/2005 | CN1610661A Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| 04/27/2005 | CN1610659A Carboxylic acid derivative |
| 04/27/2005 | CN1610545A Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor |
| 04/27/2005 | CN1610541A Novel chromium (III) alpha amino acid complexes |
| 04/27/2005 | CN1609616A Specific markers for diabetes |
| 04/27/2005 | CN1609206A Crystal structure of oxidosqualene cyclase |
| 04/27/2005 | CN1609114A Notoginseng leaf total flavone and its prepn and application |
| 04/27/2005 | CN1608676A Orally taken carrier to transduce liver and intestine cell |
| 04/27/2005 | CN1608660A Compound medicine prepn for treating diabetes and its prepn process |
| 04/27/2005 | CN1608644A Medicine capsule for treating diabetes |
| 04/27/2005 | CN1608642A Composition with function of regulating blood sugar |
| 04/27/2005 | CN1608638A Blood cleaning metabolism bolus |
| 04/27/2005 | CN1608614A New slimming effervescent tablet form |
| 04/27/2005 | CN1608513A Health food containing hyaluronic acid and dermatan sulfate |
| 04/27/2005 | CN1198843C Method for chromatographically purifying insulins |
| 04/27/2005 | CN1198820C N-substituted nitrogen heterocyclic compound |
| 04/27/2005 | CN1198819C Benzimidazole derivatives |